S875
Clinical - Mixed sites & palliation
ESTRO 2026
treated patients are still alive beyond our expectations. Material/Methods: Six patients with melanoma, hepatocellular-carcinoma, NSCLC, SCLC and myxofibrosarcoma, previously progressing on systemic therapies, were treated between May-November 2025. They were primarily intended for conventional radiotherapy which could not be applied due to the very poor DVH-profile. Mainly, the dose prescription was a single fraction 20- 24Gy at 70%-isodose delivered to the central tumor segment designed by contracting the GTV by 8-10mm. All tumors were highly-aggressive, symptomatic, fast- growing under systemic therapies and had a diameter >6cm (range: 6-12). The same, previously failed immune- or targeted therapy was continued seven days after PTI or later. Results: Restaging-CT/MRI data are currently available for the first four patients. Their mean follow up was 4 months (range: 2-6). For the remaining two will be available during the current month. Three of those four patients with HCC, SCLC and melanoma responded to therapy with 65%-, 85%-, and 100%-tumor volume reductions, respectively (Fig. 1, 2). Disease status at last follow up
Conclusion: What can be concluded, obviously limited to a short follow-up and a small number of patients, is that a single fraction PTI in combination with immuno- /targeted therapy was feasible and safe with minimal side effects that did not affect quality of life. 1-day treatment was effective showing fast symptom relief and strong neoadjuvant effect with potential to convert unresectable, highly-palliative into resectable, potentially curable disease. The manifestation of the abscopal effect indicates the immunomodulatory potential of this technique. Keywords: Partial Tumor Irradiation, Immunomodulation Early Changes in Quality of Life Following Cancer Diagnosis: A Prospective Comparative Study. Albana Fico 1 , Fatjona Kraja 2,3 , Bledar Kraja 1,4 , Ervin Toci 5 , Helidon Nina 2,3 , Silvana Çeliku 2 , Florina Hoxha 3 , Edit Zaganjori 3 , Athina Papadhopullo 3 , Adil Brahimi 3 , Erald Karaulli 3 , Bledi Kreka 3 , Artur Xhumari 6,7 1 Biomedical and Experimental Sciences, Faculty of Medicine, University o Medicine, Tirana, Albania. 2 Surgery, Faculty of Medicine, University o Medicine, Tirana, Albania. 3 Oncology, UHC Mother Teresa, Tirana, Albania. 4 Gastroenterology and Hepatology, UHC Mother Teresa, Tirana, Albania. 5 Public Health, Faculty of Medicine, University o Medicine, Tirana, Albania. 6 Neurosurgery, Faculty of Medicine, University o Medicine, Tirana, Albania. 7 Neurosurgery, UHC Mother Teresa, Tirana, Albania Digital Poster 1772 Purpose/Objective: To evaluate changes in quality of life (QoL) among cancer patients from baseline at diagnosis to three months after diagnosis, and to identify demographic, clinical, and treatment-related factors associated with
was regression. The fourth patient with myxofibrosarcoma presented an image of
pseudoprogression on his only restaging-CT scan 6 weeks after treatment. His tumor was swollen and widely necrotic-colliquative. A SCLC patient presented with two lymphnodal abscopal effects after PTI before immunotherapy was given. Side effects were G2- nausea (retroperitoneal melanoma) and G1-pain (chest wall myxofibrosarcoma). The remaining 4 patients did not manifest any side effects.
QoL improvement. Material/Methods:
A prospective observational study was conducted in 250 cancer patients in the framework of the Albanian
Made with FlippingBook - Share PDF online